Phase III Study Results of Imiquimod Creams for Treatment of EGW Presented at HPV Conference

Published July 9, 2010

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference
Results from a Phase III program evaluating imiquimod 3.75% and 2.5% creams for the treatment of EGW, applied once daily for up to 8 weeks, demonstrated that both were well-tolerated and more efficacious than placebo, according to data presented at the annual Human Papillomavirus Conference in Montreal, July 3 – 8. Investigators found that efficacy was greatest for imiquimod 3.75% with an …
Read more on News-Medical-Net

Drug Study Shows Improvement in Major Orthopedic Surgery Care
HAMILTON, Canada, July 9, 2010 /PRNewswire/ — An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being led by a steering committee chaired by McMaster University professor Dr. Alexander Turpie. The follow-up analysis of three recently completed international clinical …
Read more on redOrbit